EX-99.1 2 dp09560_ex9901.htm
 
EXHIBIT 99.01
 

Hampshire International Business Park
Chineham  Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
   
Press Release
  
   
 
FIRST QUARTER 2008 RESULTS DATE NOTIFICATION
25 April 2008
 
Basingstoke, UK and Philadelphia, US – April 16, 2008 – Shire plc (LSE: SHP, NASDAQ: SHPGY) will announce first quarter 2008 earnings on Friday 25 April 2008.
 
Results press release will be issued at:
12:00 BST / 07:00 EDT
   
Investor conference call time:
14:00 BST / 09:00 EDT
 
 
Live conference call for investors:
 
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the live conference call for investors at 14:00 BST/9:00 EDT.
 
Please RSVP ssalah@shire.com (T: +44 (0)1256 894 160) for this conference call.
 
The details of the live conference call are as follows:
 
UK and International dial in
+44 (0)2030234496
   
US dial in
1 8669665335
   
Password/Conf ID
Shire
 
Live Webcast:
 
The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investors section.  A slide presentation to accompany the call will also be available on the Shire website.
 
 
 
 
Registered in England 5492592  Registered Office as above
 
Replay:
 
A replay of the presentation will be available for two weeks.  Details are as follows:
 
UK and International dial in
44-20-8196-1998
   
US dial in
1-866-583-1035
   
Pin code
3008632#
   
Webcast replay
www.shire.com, in the investors section

 

 
 
For further information please contact:

Investor Relations
Souheil Salah (Rest of the World)
+44 1256 894 160
     
 
Emily Berish (North America)
+1 484 595 8546

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.  Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com
 
 
 
 
Registered in England 5492592  Registered Office as above